Loading organizations...
Fosun Pharma is a global pharmaceutical and healthcare industry group based in Shanghai, China, that develops and operates businesses across pharmaceuticals, medical devices, and medical diagnosis. The enterprise operates as a dual-listed public company, trading A shares on the Shanghai Stock Exchange since 1998 and H shares on the Hong Kong Stock Exchange since 2012. The corporation expands its global footprint through strategic acquisitions and partnerships, notably purchasing a 49% stake in the pharmaceutical distributor Sinopharm Group in 2003. Additionally, the firm acquired the Africa-focused French drug distributor Tridem Pharma for up to €63 million in 2017 and partnered with Insilico Medicine in 2021 to facilitate its entry into the Chinese market. Fosun Pharma was established in 1994 by co-founders Guo Guangchang, Liang Xinjun, Wang Qunbin, Fan Wei, and Tan Jian.
Key people at Fosun Pharma.
Fosun Pharma was founded in 1994 by Guo Guangchang (Founder).
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company founded in 1994, operating in pharmaceuticals, medical devices & diagnostics, and healthcare services.[1][2][4] It serves patients worldwide by addressing unmet needs in core areas like oncology (solid tumors and hematologic malignancies) and immune-inflammatory disorders through an open, globally integrated R&D ecosystem focused on antibody/ADC platforms, cell therapies, small molecules, radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery.[1][4] The company implements a “4IN” strategy—Innovation, Internationalization, Intelligentization, and Integration—rooted in China with operations in the US, Europe, Africa, India, and Southeast Asia, enhanced by its alliance with Sinopharm Group for pharmaceutical commerce; its mission is "Better Health for Families Worldwide," guided by values of care for life, continuous innovation, pursuit of excellence, and sustainable partnership.[1][3][4]
Fosun Pharma's growth momentum is evident in its 30-year evolution from pharmaceutical manufacturing to a multifaceted healthcare group, with key products spanning innovative drugs, vaccines, medical beauty, respiratory health, in vitro diagnostics, and health services; it has earned accolades like inclusion in the 2018 World's Best Employers List and China's Top Pharmaceutical lists.[3][6]
Fosun Pharma began in 1994 in Shanghai with a mission to enhance human health, initially focusing on pharmaceutical manufacturing and research.[1][2] Originally named Shanghai Fortune Industrial Joint-Stock Co., Ltd. (later transliterated to Fosun), it went public with A-shares in 1998 and H-shares in 2012, marking its transition to a pharmaceutical powerhouse.[5] Pivotal early moments included acquiring a 49% stake in Sinopharm Group in 2003 (shifting to ownership of its parent by 2008) and strategic global expansions, such as the 2016-2017 acquisition of 74% of Indian firm Gland Pharma for up to US$1.09 billion—the largest Indian corporate takeover by a Chinese company at the time—and the 2017 purchase of Africa-focused Tridem Pharma for up to €63 million.[5] A 2021 partnership with Insilico Medicine aided its entry into AI-driven drug discovery in China, building on decades of rooting in China while globalizing.[1][5]
Fosun Pharma rides the wave of global healthcare innovation, particularly in precision oncology, immunotherapy, and emerging modalities amid rising demand for targeted therapies against cancer and autoimmune diseases.[1][4][6] Its timing aligns with China's push for biotech self-reliance and post-pandemic globalization of R&D, leveraging overseas markets to bypass domestic hurdles while importing expertise via acquisitions like Gland Pharma.[5] Market forces favoring it include aging populations driving oncology needs, AI acceleration in drug discovery, and radiopharma/RNA booms; it influences the ecosystem by fostering open platforms, partnering with funds and firms like Insilico, and integrating services with pharma commerce, positioning China as a biotech exporter.[1][5]
Fosun Pharma is poised to solidify as a global leader in integrated pharma-healthcare innovation, advancing its “4IN” engine with AI, gene editing, and radiopharma pipelines to capture growth in oncology and immunology.[1][4] Trends like AI-drug discovery synergies, US-China biotech decoupling (favoring its multi-region ops), and demand for affordable next-gen therapies will shape its path, potentially through more M&A and modality breakthroughs. Its influence may evolve by bridging Eastern manufacturing scale with Western R&D, delivering better health for families worldwide—echoing its 1994 mission amid 30 years of relentless expansion.[1][6]
Key people at Fosun Pharma.
Fosun Pharma was founded in 1994 by Guo Guangchang (Founder).
